These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 21182340)

  • 1. A review of economic evaluations of darunavir boosted by low-dose ritonavir in treatment-experienced persons living with HIV infection.
    Mauskopf J; Annemans L; Hill AM; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():1-16. PubMed ID: 21182340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial.
    Brogan A; Mauskopf J; Talbird SE; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():129-46. PubMed ID: 21182348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Hemmett L; Hjelmgren J; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():147-67. PubMed ID: 21182349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA.
    Mauskopf J; Brogan A; Martin S; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():83-105. PubMed ID: 21182346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of darunavir/ritonavir 600/100 mg bid in protease inhibitor-experienced, HIV-1-infected adults in Belgium, Italy, Sweden and the UK.
    Moeremans K; Annemans L; Löthgren M; Allegri G; Wyffels V; Hemmet L; Caekelbergh K; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():107-28. PubMed ID: 21182347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs to achieve undetectable HIV RNA with darunavir-containing highly active antiretroviral therapy in highly pretreated patients: the POWER experience.
    Hill AM; Clotet B; Johnson M; Stoll M; Bellos N; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():69-81. PubMed ID: 21182345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting direct costs of HIV care during the first year of darunavir-based highly active antiretroviral therapy using CD4 cell counts: evidence from POWER.
    Hill AM; Gebo K; Hemmett L; Löthgren M; Allegri G; Smets E
    Pharmacoeconomics; 2010; 28 Suppl 1():169-81. PubMed ID: 21182350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modelling the budget impact of darunavir in the treatment of highly treatment-experienced, HIV-infected adults in France.
    Colin X; Lafuma A; Costagliola D; Smets E; Mauskopf J; Guillon P
    Pharmacoeconomics; 2010; 28 Suppl 1():183-97. PubMed ID: 21182351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States.
    Brogan AJ; Mrus J; Hill A; Sawyer AW; Smets E
    HIV Clin Trials; 2010; 11(3):133-44. PubMed ID: 20736150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative cost-effectiveness analysis between darunavir/ritonavir and other protease inhibitors in treatment-naive human immunodeficiency syndrome type 1-infected patients in Spain].
    Smets E; Brogan AJ; Hill A; Adriaenssen I; Sawyer AW; Domingo-Pedrol P; Gostkorzewicz J; Ledesma F
    Enferm Infecc Microbiol Clin; 2013; 31(7):430-6. PubMed ID: 23260386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomics of darunavir.
    Fullerton DS; Smets E; De La Rosa G; Mrus JM
    Expert Rev Pharmacoecon Outcomes Res; 2011 Feb; 11(1):27-39. PubMed ID: 21351854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-minimization comparison of darunavir plus ritonavir and lopinavir/ritonavir in HIV-1 infected treatment-naïve women of childbearing age.
    Möller J; Desai K; Simpson K; Baran RW; Van de Steen O; Dietz B; Gooch K
    J Med Econ; 2014 Apr; 17(4):250-8. PubMed ID: 24351091
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability, and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
    Rachlis A; Clotet B; Baxter J; Murphy R; Lefebvre E
    HIV Clin Trials; 2007; 8(4):213-20. PubMed ID: 17720661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada.
    Brogan AJ; Smets E; Mauskopf JA; Manuel SA; Adriaenssen I
    Pharmacoeconomics; 2014 Sep; 32(9):903-17. PubMed ID: 24906477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States.
    Simpson KN; Pei PP; Möller J; Baran RW; Dietz B; Woodward W; Migliaccio-Walle K; Caro JJ
    Pharmacoeconomics; 2013 May; 31(5):427-44. PubMed ID: 23620210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Darunavir as first-line therapy. The TITAN study].
    Curran A; Ribera Pascuet E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():14-22. PubMed ID: 19195455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of costs by CD4 count category for the darunavir/r 600/100 mg bid and control protease inhibitor arms of the POWER 1 and 2 trials.
    Hill A; Hemmett L; Wilson B
    HIV Clin Trials; 2007; 8(5):303-10. PubMed ID: 17956831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain.
    Pasquau J; Gostkorzewicz J; Ledesma F; Anceau A; Hill A; Moecklinghoff C
    Appl Health Econ Health Policy; 2012 Mar; 10(2):139-41. PubMed ID: 22293019
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.